Antimicrobial resistance in Canada

CMAJ. Canadian Medical Association Journal

Volumn 167, Issue 8, 2002, Pages 885-891

  Conly, John ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; METICILLIN; PENICILLIN G; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CANADA; DRUG USE; ECONOMIC ASPECT; ENTEROCOCCUS; EPIDEMIC; GENE MUTATION; HEALTH PROGRAM; HEALTH PROMOTION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OUTPATIENT; PRESCRIPTION; PREVALENCE; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 0036431852     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Fleming A. Penicillin. Nobel Lecture, December 11, 1945. In: Nobel e-museum. Available: www.nobel.se/medicine/laureates/1945/fleming-lecture.pdf (accessed 2002 July 28)
2. World Health Organization: Overcoming antimicrobial resistance. Report on infectious diseases 2000. Available: www.who.int/infectious-disease-report/2000/index.html (accessed 2002 July 28)
3. American Society for Microbiology. Report of the ASM Task Force on Antimicrobial Resistance. Antimicrob Agents Chemother 1995;Suppl:1-23.
4. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996;275:234-40.
5. Swartz MN. Use of antimicrobial agents and drug resistance. N Engl J Med 1997;337:491-2.
6. Kunin CM. Resistance to antimicrobial drugs - a worldwide calamity. Ann Intern Med 1993;118:557-61.
7. Centers for Disease Control and Prevention. Addressing emerging infectious disease threats: a prevention strategy for the United States [executive summary]. Morbid Mortal Wkly Rep 1994;43(R18).
8. Central Intelligence Agency. The global infectious disease threat and its implications for the United States. Available: www.odci.gov/cia/publications/nie/report/nie99-17d.html (accessed 2002 July 28)
9. Murray BE. What can we do about vancomycin-resistant enterococci? Clin Infect Dis 1995;20:1134-6.
10. Pallares R, Dick R, Wenzel RP, Adams JR, Nettleman MD. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol 1993;14:376-82.
11. Simor AE, Ofner-Agostini M, Bryce E, Green K, McGeer A, Mulvey M, et al. The evolution of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 5 years of national surveillance. CMAJ 2001;165(1):21-6.
12. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.
13. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994;264:375-82.
14. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994;264:388-93.
15. Dowson CG, Coffey TJ, Spratt BG. Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to beta-lactam antibiotics. Trends Microbiol 1994;2:361-6.
16. Munoz R, Dowson CG, Daniels M, Coffey TJ, Martin C, Hakenbeck R, et al. Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae. Mol Microbiol 1992;6:2461-5.
17. Brumfitt W, Hamilton-Miller JMT. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989;320:1188-96.
18. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States 1989-93. Morbid Mortal Wkly Rep 1993;42:597-9.
19. Chenowth C, Schaberg D. The epidemiology of enterococci. Eur J Clin Microbiol Infect Dis 1990;9:80-9.
20. Moellering RC Jr. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 1992;28:1-12.
21. Williamson R, Le Bouguenec C, Gutmann L, Horaud T. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin. J Gen Microbiol 1985;131:1933-40.
22. Gardam MA, Conly JM. An update on the emergence of glycopeptide resistance in enterococci. Curr Infect Dis Rep 1999;1:319-27.
23. Panlilio AL, Culver DG, Gaynes RP, Banerjee S, Henderson TS, Tolson Js, et al. Methicillin-resistant Staphylococcus aureus in US hospitals 1975-1991. Infect Control Hosp Epidemiol 1992;13(10):582-6.
24. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994;13:50-5.
25. Low DE, Garcia M, Callery S, et al. Methicillin-resistant Staphylococcus aureus - Ontario. Can Dis Wkly Rep 1981;7:249-50.
26. Vortel JJ, Bell A, Farley JD, Shaw C, Guite A, Harper B. Methicillin-resistant Staphylococcus aureus (MRSA) in a British Columbia hospital - 1990. Can Dis Wkly Rep 1991;17:71-2.
27. Simor AE, Augustin A, Ng J, Betschel S, McArthur M. Control of MRSA in a long-term care facility. Infect Control Hosp Epidemiol 1994;15:69-70.
28. The Canadian Nosocomial Infection Surveillance Program. Results of the first 18 months of surveillance for methicillin-resistant Staphylococcus aureus in Canadian hospitals. Can Commun Dis Rep 1997;23:41-6.
29. Preston M, Borczyk A, Jamieson F. Epidemic methicillin-resistant Staphylococcus aureus strain - Ontario. Can Commun Dis Rep 1998;24:47-9.
30. Martone WJ. Spread of vancomycin-resistant enterococci: Why did it happen in the United States? Infect Control Hosp Epidemiol 1998;19:539-45.
31. Kibsey PC, Willey B, Low DE, Cain D, Boychuk LR, Heule M. Vancomycin-resistant Enterococcus faecium: first Canadian isolate [abstract K5]. 61st Conjoint Meeting on Infectious Diseases. Canadian Association for Clinical Microbiology and Infectious Diseases; 1993 Nov 8-10; Vancouver.
32. Lior L, Litt M, Hockin J, Kennedy C, Jolley BA, Garcia M, et al. Vancomycin-resistant enterococci on a renal ward in an Ontario hospital. Can Commun Dis Rep 1996;22:125-8.
33. Ofner-Agostini ME, Conly J, Paton S, Johnston L, Mulvey M, Nicolle L, et al. Vancomycin-resistant enterococci (VRE) in Canada - results of the Canadian Nosocomial Infection Surveillance Program 1996: VRE point prevalence surveillance project. Can J Infect Dis 1997;8:73-8.
34. Conly JM, Ofner ME, Paton S, Johnston L, Mulvey M, Kureishi A, et al. The emerging epidemiology of vancomycin-resistant enterococci in Canada 1993-1998: results from the Canadian Nosocomial Infection Surveillance Program (CNISP) Passive Reporting Network. Can J Infect Dis 2001;12:364-70.
35. Johnston L, Conly J. The emerging epidemiology of vancomycin-resistant enterococci in Canada revisited. Can J Infect Dis 2000;11:127-31.
36. Wang E, Kellner JD, Arnold S. Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice. Can Fam Physician 1998;44:1881-8.
37. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002;50(Suppl 1):1-5.
38. Simor AE, Louie M, Low DE. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network. Antimicrob Agents Chemother 1996;40:2190-3.
39. Low D. Decreasing penicillin and macrolide resistance in Canada: Who's driving whom? Can Bact Surv Network Newsl 1999.
40. Hoban D, Karlowsky JA, Nichol K, Palatnick LP, Low DE, Zhanel GG. Decreasing incidence of penicillin-resistant and multidrug-resistant Streptococcus pneumoniae in Canada: results of an ongoing national surveillance study 1997-2000 [abstract 1808]. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto. p. 113.
41. Threlfall EJ, Frost JA, Ward LR, Rowe B. Increasing spectrum of resistance in multiresistant Salmonella typhimurium. Lancet 1996;347:1052-3.
42. Wall PG, Threlfall EJ, Ward LR, Rowe B. Multiresistant Salmonella typhimurium DT104 in cats: a public health risk. Lancet 1996;348:471.
43. Centers for Disease Control and Prevention. Multidrug-resistant Salmonella serotype Typhimurium - United States, 1996. JAMA 1997;277:1513.
44. Division of Emerging and Other Communicable Disease Surveillance and Control, World Health Organization. The medical impact of the use of antimicrobials in food animals: report and proceedings of a WHO meeting [document no. WHO/EMC/ZOO/97.4]; 1997 Oct 13-17; Berlin, Germany. Geneva: WHO; 1997.
45. Griggs DJ, Gensberg K, Piddock LJV. Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from humans and animals. Antimicrob Agents Chemother 1996;40:1009-13.
46. Mølbak K, Baggesen DL, Aarestrup FM, Ebbesen JM, Engberg J, Frydendahl K, et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype Typhimurium DT104. N Engl J Med 1999;341:1420-5.
47. Twells L. Assessment of the burden of illness of antibiotic resistance in Canada. Report to Health Canada and the Canadian Committee on Antibiotic Resistance, 2001.
48. Kim T, Oh P, Simor A. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001;22:99-104.
49. Gillis G, Eng-Chong M, Henseleit S, Mccumber T, Smith M, Conly J. Financial impact of an outbreak of vancomycin-resistant Enterococcus (VRE) colonization and infection in an inpatient/ambulatory dialysis program [abstract J-86]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sept 28-Oct 1; Toronto. p. 304.
50. Nelson M. Action needed on superbugs, researchers say. Globe and Mail [Toronto]. 2001 May 30;Sect A:19.
51. US Office of Technology Assessment. Chaps 1, 2, 7. In: Impacts of antibiotic-resistant bacteria. Washington: US Government Printing Office; 1995.
52. Wenzel RP, Edmond MB. Managing antimicrobial resistance. N Engl J Med 2000;343:1961-3.
53. Baird RW. Antibiotic prescribing, controls, and antimicrobial resistance: an Australian experience. Alliance for the Prudent Use of Antibiotics Newsl 1997;15(4):1-6.
54. IMS HEALTH Canada. Antibiotic use on the decline as 2000 flu season starts. Available: www.imshealthcanada.com/htmen/4_2_1_21_old.htm (accessed 2002 July 28)
55. IMS HEALTH Canada and Canadian Committee on Antibiotic Resistance. Antibiotic use data by region and by product class from 1996 to December 2000 is now available. Available: www.ccar-ccra.org/powerpoint/RDS_Dec2002.ppt (accessed 2002 July 28)
56. Population. In: Canadian Statistics [Web site for Statistics Canada] Available: www.statcan.ca/english/Pgdb/People/popula.htm (accessed 2002 July 28)
57. Health Canada and the Canadian Infectious Disease Society. Controlling antimicrobial resistance: an integrated action plan for Canadians. Can Commun Dis Rep 1997;23:S7.
58. Institute of Medicine. Human health risks with the subtherapeutic use of penicillins and tetracyclines in animal feeds. Washington: National Academy Press; 1980.
59. Union of Concerned Scientists. Hogging it. Estimates of antimicrobial abuse in livestock. Cambridge (MA): UCS Publications; 2001.
60. Khachatourians G. Agricultural use of antibiotics and the evolution of antibiotic-resistant bacteria. CMAJ 1998;159:1129-36.
61. Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 2001;32:1201-6.
62. Threlfall EJ, Ward LR, Frost JA, Willshaw GA. The emergence and spread of antibiotic resistance in food-borne bacteria. Int J Food Microbiol 2000;62(1-2):1-5.
63. US Congress, Office of Technology Assessment. Drugs in livestock feed. Washington: US Government Printing Office; 1979.
64. Agriculture and Agri-Food Canada. Annual report on chemical and biological testing of agri-food commodities, 1992/1993. Ottawa: Agri-Food Safety and Strategies Division, Agriculture and Agri-Food Canada; 1993.
65. Weinstein RA. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg Infect Dis 2001;7:188-92.
66. Albert RK, Condie F. Hand-washing patterns in medical intensive-care units. N Engl J Med 1981;304:1465-6.
67. Sproat LJ, Inglis TJ. A multicentre survey of hand hygiene practice in intensive care units. J Hosp Infect 1994;26:137-48.
68. Jarvis WR. Handwashing: The Semmelweis lesson forgotten? Lancet 1994; 344:1312-3.
69. Conly J, Hill S, Ross J, Leitzman J, Louie TJ. Handwashing practices in an intensive care unit: the effects of an educational program and its relationship to infection rates. Am J Infect Control 1989;11:191-3.
70. Goldmann DA. Hand-washing and nosocomial infections. N Engl J Med 1992;327:120-2.
71. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-53.
72. Weinstein RA. Epidemiology and control of nosocomial infections in adult intensive care units. Am J Med 1991;30:2525-8.
73. Haley RW, Cushion NB, Tenover FC. Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit. J Infect Dis 1995;171:614-24.
74. Vicca AF. Nursing staff workload as a determinant of methicillin-resistant Staphylococcus aureus spread in an adult intensive therapy unit. J Hosp Infect 1999;43:109-13.
75. Li J, Birkhead GS, Strogatz DS, Coles FB. Impact of institution size, staffing patterns, and infection control practices on communicable disease outbreaks in New York State nursing homes. Am J Epidemiol 1996;143:1042-9.
76. Taylor GD, McKenzie M, Kirkland T, Buchanan-Chell M, Wiens R. The impact of health care restructuring on nosocomially acquired blood stream infections. Can J Infect Dis 2000;11:34-7.
77. Fridkin SK, Pear SM, Williamson TH, Galgiani JN, Jarvis WR. The role of understaffing in central venous catheter-associated bloodstream infections. Infect Control Hosp Epidemiol 1996;17:150-8.
78. Needleman J, Buerhaus P, Mattke S, Stewart M, Zelevinsky K. Nurse staffing and patient outcomes in hospitals. Harvard School of Public Health. Final Report for Health Resources Services Administration, US Department of Health and Human Services [contract 230-99-0021]. Available: bhpr.hrsa.gov/nursing/staffstudy.htm (accessed 2002 July 28)
79. Herwaldt LA, Smith SD, Carter CD. Infection control in the outpatient setting. Infect Control Hosp Epidemiol 1998;19:41-74.
80. Moberg CL, Dubos R. A harbinger of microbial resistance to antibiotics. Microb Drug Resist 1996;2:287-97.
81. Levy S. Antibiotic resistance: an ecological imbalance. Ciba Found Symp 1997;207:1-14.
82. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA 1995;274:700-5.
83. Hutchinson JM, Foley RN. Methods of physician remuneration and rates of antibiotic prescription. CMAJ 1999;160:1013-7.
84. Blondel-Hill EM, Fryters SR, Mitchell S, Carson MM, Tomney M. Do bugs need drugs? A community project for the wise use of antibiotics. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sept 26-29; San Francisco. p. 735.
85. Stewart J, Pilla J, Dunn L. Pilot study for appropriate anti-infective community therapy; effect of a guideline-based strategy to optimize use of antibiotics. Can Fam Physician 2000;46:851-9.
86. The bacteria won't die [editorial]. Globe and Mail [Toronto] 2000 Jun 19;Sect A:12.